7 results
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
10 Nov 22
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:10pm
in China) Design Phase 1b/2 open-label study in advanced mPDAC patients of Chinese ethnicity Study Size 50 subjects (~15 sites) Endpoints Primary
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
added to SoC in Chinese patients with mPDAC Design Phase 1b/2a open-label study in advanced mPDAC patients of Chinese ethnicity testing SoC
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm
Design Phase 1b/2a open-label study in advanced mPDAC patients of Chinese ethnicity testing SoC chemotherapy (gemcitabine + Qilu-produced nab
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
in advanced mPDAC patients of Chinese ethnicity testing SoC chemotherapy (gemcitabine + Qilu-produced nab-paclitaxel) in combination with LSTA1 Study
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
2 Nov 23
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
of Chinese ethnicity testing SoC chemotherapy (gemcitabine + Qilu-produced nab-paclitaxel) in combination with LSTA1 Study Size 50 subjects (~15 sites
8-K
EX-99.2
jv0cb1a5o byvecq8f
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.2
ju7 0w6cm2
9 May 24
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:08pm
- Prev
- 1
- Next